Development of a Ternary Solid Dispersion Formulation of LW6 to Improve the In Vivo Activity as a BCRP Inhibitor: Preparation and In Vitro/In Vivo Characterization

LW6 (3-[2-(4-adamantan-1-yl-phenoxy)-acetylamino]-4-hydroxy-benzoic acid methyl ester) is a potent inhibitor of drug efflux by the breast cancer resistance protein (BCRP). However, its poor aqueous solubility leads to low bioavailability, which currently limits in vivo applications. Therefore, the p...

Descripción completa

Detalles Bibliográficos
Autores principales: Bajracharya, Rajiv, Lee, Sang Hoon, Song, Jae Geun, Kim, Minkyoung, Lee, Kyeong, Han, Hyo-Kyung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6572573/
https://www.ncbi.nlm.nih.gov/pubmed/31052438
http://dx.doi.org/10.3390/pharmaceutics11050206

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6572573/
https://www.ncbi.nlm.nih.gov/pubmed/31052438
http://dx.doi.org/10.3390/pharmaceutics11050206

Ejemplares similares